Poh, Mau Ern and Liam, Chong Kin and Rajadurai, Pathmanathan and Chai, Chee Shee (2018) Epithelial-to-mesenchymal transition (EMT) causing acquired resistance to afatinib in a patient with epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma. Journal of Thoracic Disease, 10 (7). E560-E563. ISSN 2072-1439, DOI https://doi.org/10.21037/jtd.2018.06.122.
Full text not available from this repository.Abstract
We report the first case of epithelial-to-mesenchymal transition (EMT) as the cause of acquired resistance to the second-generation EGFR-tyrosine kinase inhibitor (TKI), afatinib in a patient with advanced non-small cell lung cancer (NSCLC) harboring a sensitizing EGFR mutation. Patients with EGFRmutant NSCLC inevitably develop acquired resistance while on EGFR-TKI treatment. EMT which renders cancer cells more invasive and migratory is one of the mechanisms of acquired resistance to EGFR-TKIs and correlates with a poor prognosis. Possible therapeutic strategies in patients with EMT include blocking M2 muscarinic receptor signalling, targeting EMT with histone deacetylase inhibitors such as entinostat and MEK-inhibitors such as selumetinib, inhibition of microRNAs, immunotherapy and inhibiting fibroblast growth factor receptor-1.
| Item Type: | Article |
|---|---|
| Funders: | UNSPECIFIED |
| Uncontrolled Keywords: | Acquired resistance; Afatinib; EGFR mutation; Epithelial-to-mesenchymal transition (EMT); Lung adenocarcinoma |
| Subjects: | R Medicine |
| Divisions: | Faculty of Medicine |
| Depositing User: | Ms. Juhaida Abd Rahim |
| Date Deposited: | 19 Apr 2019 01:35 |
| Last Modified: | 23 Mar 2021 02:26 |
| URI: | http://eprints.um.edu.my/id/eprint/21020 |
Actions (login required)
 |
View Item |
